ABSTRACT
Introduction
Cordyceps sinensis, a fungus parasitized on the larva of Lapidoptera, has been used as a valued traditional Chinese medication and a tonic food. Natural products of Cordyceps sinensis are so rare and difficult to obtain in uniform composition that cultured products have been developed. In 1987, CordyMax Cs-4, a mycelial fermentation product of Cordyceps sinensis, was approved by the National New Drug Review and Approval committee of the Chinese Ministry of Public Health, and has been used in clinics for fatigue, night sweating, male and female hyposexuality including impotence, hyperglycemia, hyperlipidemia, asthenia after severe illness, respiratory diseases, renal dysfunction and renal failure, arrhythmias and other heart diseases, and liver diseases [1] . However, we focused on the cultural fruiting body of Cordyceps sinensis instead of the mycelium and reported the anticancer effect of water extracts of Cordyceps sinensis (WECS) on mouse Lewis lung carcinoma (LLC) cells and B16 mouse melanoma cells [2] .
In this study, we tried to elucidate the mechanism of the anticancer effect of WECS and speculated an active ingredient in WECS. In particular, we investigated pharmacologically whether WECS stimulate adenosine A 3 receptor (A 3 -R) using a selective A 3 -R antagonist since an effective component in WECS, cordycepin (3'-deoxyadenosine), showed anticancer action via the stimulation of A 3 -R, according to our previous experimental data [3] . Finally, we quantified the content of cordycepin in WECS using the HPLC-ECD system.
Materials and Methods

Chemicals
Dried fruiting bodies of cultured Cordyceps sinensis were
Cordyceps sinensis Acts as an Adenosine A Receptor Agonist on Mouse Melanoma and 267 3 Lung Carcinoma Cells, and Human Fibrosarcoma and Colon Carcinoma Cells produced by Jiang Men Baode Biological Technology (Guangdong, China). They were extracted with hot water (70˚C) for 5 min and the extract was then filtered and lyophilized. The lyophilized powder (WECS) was sealed in bottles and kept in a refrigerator (4˚C) until use. 3-Ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(±)-dihydropyridine-3,5-di-carboxylate (MRS1191, a selective A 3 -R antagonist), cordycepin (3'-deoxyadenosine), adenosine and fetal bovine serum (FBS) were purchased from Sigma Chemical Co. (St. Louis, MO). Dulbecco's modified Eagle's medium (DMEM) with L-glutamine, Earle's minimum essential medium (EMEM) plus glutamax, RPMI1640 medium and MEM non-essential amino acids (NEAA) 100 × solution were from Invitrogen Co. (Grand Island, NY). Dulbecco's phosphatebuffered saline without calcium and magnesium [DPBS (-)] was from Nissui Pharmaceutical Co., Ltd (Tokyo, Japan). EDTA trypsin solution (EDTA, 0.02%; trypsin, 0.1%) and penicillin/streptomycin solution (penicillin, 50,000 U/mL; streptomycin, 50 mg/mL) were obtained from Cosmo Bio Co., Ltd. (Tokyo, Japan).
Cells
The mouse B16-BL6 epithelial-like melanoma cell line was kindly provided by Professor Futoshi Okada of Tottori University (Yonago, Japan). The mouse Lewis lung carcinoma cell line and CW-2 human colon carcinoma cell line were provided by the RIKEN CELL BANK (Tsukuba, Japan). The human HT1080 epithelial-like fibrosarcoma cell line was purchased from DS Pharma Biomedical Co., Ltd. (Suita, Japan). B16-BL6 cells were cultured in DMEM containing 10% FBS and a 0.1% penicillin/streptomycin solution. LLC cells were cultured in DMEM containing 10% FBS. HT1080 cells were cultured in EMEM containing 10% FBS and a 1% NEAA. CW-2 cells were cultured in RPMI1640 containing 10% FBS.
Growth Curves of B16-BL6 Cells, LLC Cells, HT1080 Cells and CW-2 Cells
Sub-confluent cancer cells were harvested with EDTA trypsin solution and resuspended as 1 × 10 5 cells/2 mL in each well of a 12-well culture plate, and then treated with 10 µg/mL WECS. MRS1191 (0.1 and 1 µM) was added to the wells 30 min before the addition of WECS. To evaluate the effect of MRS1191 alone on cell growth, 0, 0.1, 1 and 10 μM of MRS1191 were added to each culture plate at 0 h. After 24, 48 and 72 h incubation at 37˚C, viable cells were counted with a Coulter counter (Coulter Z1; Beckman Coulter, Inc., Tokyo, Japan).
Determination of Cordycepin and Adenosine Content in WECS
HPLC with electrochemical detection (HPLC-ECD) was used to quantify cordycepin and adenosine in WECS, according to a previously described method [4] . Briefly, 20 μL of WECS (1 mg/mL) was injected into the HPLC-ECD system. The analytical column was a Cosmosil 5C18-AR-II (particle diameter, 5 μm; column size, 150 × 4.6 mm I.D.; Nacalai Tesque, Kyoto, Japan) column equipped with a guard column (10 × 4.6 mm I.D.) and the mobile phase was 20 mM sodium phosphate buffer, pH 7.0, including 10% (v/v) methanol. The flow rate was 1 mL/min and the column temperature was set at 25˚C. Quantitation of cordycepin and adenosine was performed by comparison of the peak area with those of authentic cordycepin and adenosine, respectively.
Statistical Analyses
The data are expressed as the mean ± S.D. (N = 3). Statistical analyses were performed by one-way ANOVA followed by Tukey's Multiple Comparison Test using PRISM Version 4 (GraphPad Software, Inc., San Diego, CA). Differences were considered significant at P < 0.05.
Results
In mouse cancer cell lines, WECS (10 µg/mL) inhibited the growth of B16-BL6 cells and LLC cells potently to 14% and 23% of the non-treated control at 72 h, respectively. When B16-BL6 cells were premixed with 1 µM MRS1191, a selective A 3 -R antagonist, 30 min before the addition of WECS (10 µg/mL), the cell numbers were significantly antagonized to 69% of the control value. When LLC cells were premixed with 0.1 and 1 µM MRS1191, 30 min before the addition of WECS (10 µg/mL), the cell numbers were significantly antagonized to 27% and 41% of the control value, respectively (Figure 1) . In human cell lines, WECS (10 µg/mL) inhibited the growth of HT1080 cells and CW-2 cells potently to 40% and 38% of the non-treated control at 72 h, respectively. When HT1080 cells were premixed with 1 µM MRS1191, 30 min before the addition of WECS (10 µg/mL), the cell numbers were significantly antagonized to 77% of the control value. When CW-2 cells were premixed with 0.1 and 1 µM MRS1191, 30 min before the addition of WECS (10 µg/mL), the cell numbers were significantly antagonized to 46% and 55% of the control values, respectively (Figure 2) .
In Figure 3 , showing representative data using CW-2 cells, 10 μM MRS1191 slightly reduced the cell number; however, 0.1 and 1 µM MRS1191 alone did not have any effect on cancer cell growth at 72 h. be utilized as a marker of the quality of WECS; however, cordycepin is a potent target candidate in quality checks because cordycepin was isolated as a pure compound in WECS and showed anticancer effects, and its structure and molecular weight were clarified (251.24). Accordingly, we considered cordycepin as an active ingredient showing anticancer action in WECS and tried to investigate whether the anticancer action of WECS was inhibited by A 3 -R antagonist, just like cordycepin. As a result, the anticancer effect of WECS was significantly antagonized by MRS1191, a selective A 3 -R antagonist; that is to say, cordycepin is a potent ingredient in WECS showing anticancer effects and can also be utilized as a marker for testing the quality of WECS. Actually, we determined the content of cordycepin as 2.34% w/w in WECS using the HPLC-ECD system in this experiment and it is much higher than that of adenosine (0.12% w/w in WECS).
Although it is apparent that cordycepin might be a component showing anticancer action in WECS, other components also contribute to the anticancer action of WECS.
Because the inhibitory effects of WECS on HT1080, B16-BL6, CW-2 and LLC cells were incompletely recovered to 77%, 69%, 55% and 41% of non-treated control values by addition of the selective A 3 -R antagonist, respectively, it is conceivable that the different responsibilities among the four cell lines probably occurred based on the variation in level of expression of A 3 -R on cell line membrane. We have already shown that B16-BL6 cells express A 3 -R according to a radioligand binding assay using [
125 I]-AB-MECA (a selective A 3 -R agonist) [6] and we speculate that HT1080 cells express a higher level of A 3 -R on the cell membrane than LLC, CW-2 and B16-BL6 cells due to their greatest responsibility to the selective A 3 -R antagonist.
As shown in Table 1 , the content of cordycepin and adenosine in WECS were 2.34% w/w and 0.12% w/w, respectively. WECS included cordycepin more abundant than adenosine.
Discussion
To date, we have reported that WECS inhibited the growth of B16 melanoma cells and LLC cells [2] and cordycepin (3'-deoxyadenosine), an effective ingredient in WECS, also showed anticancer effects using B16-BL6 cells and LLC cells by stimulating A 3 -R [3] . As an effective ingredient, in addition to cordycepin in WECS, Chen et al. demonstrated that polysaccharide in cultivated Cordyceps sinensis significantly inhibited hepatoma H22 tumor cell growth [5] . In fact, polysaccharide is a potent candidate in WECS showing anticancer action; however, it is still a crude ingredient and its exact structure and molecular weight cannot be determined. WECS is also a crude product and its quality needs to be checked for commercial use. In other words, polysaccharide cannot
Conclusions
We clarified that the growth inhibitory effect of WECS on B16-BL6, LLC, HT1080 and CW-2 cells was significantly antagonized by the selective A 3 -R antagonist. It is reasonable that the active ingredient in WECS indicating anticancer action might be cordycepin, which in WECS should be the target marker for testing the quality of WECS for commercial use.
